Foghorn Therapeutics Inc.
- FHTX
- NASDAQ
- Biotechnology
- Chromatin Regulation Drugs
- Clinical-Stage Biotech
$1.87
Today +1.08%Quote Oct 19, 2026, 08:00 PM UTC
−54.83%over the last month
Max drawdown −56.4%From 1-month high −55.9%3 months −63.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
106
Market value
$111.1M
Quote Oct 19
Floor
$1.84
1.6% below price
Resistance
$1.88
0.7% above price
Price vs analyst targets
12 analysts
Lowest target
$2.00Highest target
$5.00
$2.00Highest target
$5.00
- Price $1.87
- Average target $4.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 114% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FHTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free